Association between progesterone receptor expression and genomic risk differs by menopausal status in ER-positive/HER2-negative breast cancer
Breast Care · 09.11.2026
DOI: 10.1159/brc/abrag013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Care, online erschienen am 09.11.2026. Verfasst von NAOKO IWAMOTO und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Low progesterone receptor (PgR) expression is associated with higher recurrence score (RS) in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC). However, PgR expression patterns across RS categories according to menopausal status have not been fully characterized.
Methods
We retrospectively analyzed 225 patients with ER-positive/HER2-negative BC who underwent curative breast surgery and Oncotype DX testing. Associations between PgR expression and RS were evaluated according to menopausal status. Multivariable linear regression analyses were performed to identify factors independently associated with RS. The primary analysis used a uniform cutoff of RS ≥26 in both premenopausal and postmenopausal patients. An exploratory analysis additionally evaluated RS ≥16 in premenopausal patients.
Results
RS distributions were similar between premenopausal and postmenopausal patients. However, PgR expression differed significantly according to menopausal status, with median PgR expression levels of 90% and 50%, respectively (p < 0.001). Low PgR expression (≤20%) was independently associated with higher RS in both premenopausal (β = 9.2, p < 0.001) and postmenopausal patients (β = 13.4, p < 0.001). Among patients with high RS (≥26), PgR expression was significantly lower in postmenopausal than in premenopausal patients (median 4% vs. 50%, p < 0.001). The difference in PgR expression also remained significant when comparing premenopausal patients with RS ≥16 and postmenopausal patients with RS ≥26 (p < 0.001). In postmenopausal patients, low PgR expression was the only significant factor associated with RS, whereas histological grade also contributed in premenopausal patients.
Conclusion
While low PgR expression predominated in postmenopausal patients with high RS, many premenopausal patients with high RS retained high PgR expression. These findings suggest that PgR expression should be interpreted differently according to menopausal status when estimating genomic risk.
Zitieren
APA
IWAMOTO, N., Horiguchi, S., & Kuwayama, T. (2026). Association between progesterone receptor expression and genomic risk differs by menopausal status in ER-positive/HER2-negative breast cancer. Breast Care. https://doi.org/10.1159/brc/abrag013
Vancouver
IWAMOTO N, Horiguchi S, Kuwayama T. Association between progesterone receptor expression and genomic risk differs by menopausal status in ER-positive/HER2-negative breast cancer. Breast Care. 2026. doi:10.1159/brc/abrag013
BibTeX
@article{IWAMOTO2026,
author = {IWAMOTO, NAOKO and Horiguchi, Shin-ichiro and Kuwayama, Takashi},
title = {Association between progesterone receptor expression and genomic risk differs by menopausal status in ER-positive/HER2-negative breast cancer},
journal = {Breast Care},
year = {2026},
doi = {10.1159/brc/abrag013}
}
EUVIMED